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Summary.-Corynebacterium parvum was labelled by growing live bacteria in the
presence of [3H] thymidine. The bacteria were killed byformalin, washed thoroughly
and resuspended at a concentration of 7 mg dry weight/ml. An activity of 1-6 x 105
ct/min/01 ml was obtained. The biological properties (inhibition of tumour growth
and hepatosplenomegaly) of the labelled C. parvum were compared with those of
commercially available vaccine, and were found to be similar.
Labelled C. parvum was injected i.v., i.p., or s.c. into normal C57BL mice and the
localization of activity determined at 4 h and 1, 3, 7 and 14 days after injection. After
i.v. or i.p. injection, highest counts were recorded in the liver. Moderate activity
was found in the spleen, lungs and small gut. After s.c. injection, the majority of
radioactive label was detected at the site of injection and little found in other tissues.
The distribution of injected C.parvum was also studiedinmicebearingLewistumour,
and was found to be similar to that in normal mice. Moderate amounts of labelled
C. parvum were recovered from tumour. There appeared to be no relationship
between the antitumour effect of C. parvum given by a particular route of injection
and the concentration of C. parvum recovered from the tumour.
KILLED Corynebacterium parvum has
powerful antitumour effects on many
syngeneic animal tumours (Woodruff and
Boak, 1966; Smith and Scott, 1972;
Castro, 1974a) and it is now being
assessed as an anticancer agent in man
(Israel, 1975; Woodruff et al., 1975).
This vaccine has been shown in mice
to be more effective against tumours
if given i.v. or i.p. than if given s.c.
(Woodruff and Inchley, 1971; Sadler and
Castro, 1975).
C. parvum given i.v. stimulates the
RES, as judged by clearance of colloidal
carbon, and increases spleen and liver size
(Halpern et al., 1964; Castro, 1974b). It
has adjuvant properties (Howard, Scott
and C(hristie, 1973) but in defined circum-
stances appears to depress cell-mediated
immianity (Scott, 1974a; Castro, 1974b).
Little is known of the localization of
C. parvum in vivo after injection. It was
considered that such information might
lead to a better understanding of the
biological activity of this agent. There-
fore, the aim of this study was to develop
a method for radiolabelling C. parvum, to
study the biological properties of this
labelled vaccine, and to observe its
distribution in normal and tumour-bearing
mice.
MATERIALS AND METHODS
C. parvum.-Freeze-dried live C. parvum
(Wellcome, strain CN 6134) was used in the
labelling studies. Formalin-killed C. parvum
(Wellcome, strain CN 6134, batch PX 416,
7 mg dry weight/ml) was used as a control.
Radioactive labelling.-An inoculum ofthe
freeze-dried C. parvum was added to a 20 ml
suspension of Difco Bacto "cooked meat
medium" containing 5% foetal calf serum
(GibcoBiocult) and 1%glucose. After 7 days
at 37°C in a tightly sealed universal bottle,
the slurry of meat granules and bacteria was
shaken, and 2 ml of the upper layer contain-T. E. SADLER, W. A. CRAMP AND J. E. CASTRO
ing mostly bacteria was added to 100 ml of
Difco Bacto " antibiotic medium 3 " con-
taining 1% glucose. After 7 days' growth
without aeration, an 8-ml inoculum wastaken
from this culture and added to 11 fresh
medium (antibiotic medium 3 plus 1%
glucose). Deoxyadenosine 0-2mg/ml (Sigma)
was added (Boyce and Setlow, 1962), followed
by 1 juCi of [3H] thymidine (Radiochemical
Centre, Amersham, sp. act. 59 Ci/mmol)
after the deoxyadenosine had dissolved.
The bacteria were harvested 5 days later,
washed x 3 by centrifugation with 0.9%
NaCl, and finally resuspended in normal
saline containing 0.5% formalin for 7 days at
37°C. The killed cells were washed free of
formalin and resuspended in normal saline
containing 0-01% thiomersalate (BDH) as a
preservative. The final suspension was con-
centrated at 7 mg dry weight/ml. The
activity of 3 batches of labelled C. parvum
prepared at different times was between 1
and 6 x 105 ct/min/0 1 ml.
A comparison of the activity of washed
intact killed bacteria and that of the pre-
cipitate after disruption with cold 10% TCA
showed that all the activity in the bacteria
was in the form of high-mol.-wt. macro-
molecules. There was no loss of label from
C. parvum during storage. Less than 0.25%
ofthe activity present in the labelled bacteria
was found in the supernatant when the
vaccine was centrifuged 3 months after
labelling. Microscopic examination of the
killed labelled C. parvum indicated that there
was no contamination by other bacteria, and
both this radiolabelled C. parvurn and killed
but unlabelled bacteria (prepared using
similar techniques by Burroughs Wellcome)
were morphologically similar.
Mice.-Age-matched adultfemaleC57BL/
10 Sc Sn mice obtained from Olac (Southern)
Ltd were used.
Tumour.-Lewis lung carcinoma was im-
planted s.c. as a 0-1 ml homogenate in the
lower flank. It is an epidermoid tumour
which originated spontaneously as a car-
cinoma of the lung of a female C57BL mouse
at the Wistar Institute in 1951 (Sugiura and
Stock, 1955). If grown s.c., it always meta-
stasizes to the lungs (Simpson-Herren, San-
ford and Holmquist, 1974). For each animal,
2 diameters of the primary tumour were
measured twice weekly and the mean dia-
meter calculated. Macroscopic surface lung
metastases were counted 21 days after tumour
implantation, after staining the lungs by
inflation with a dilute solution of Indian ink
and fixation in Fekete's solution (Wexler,
1966). The number of metastases in the
different experimental groups was compared
by Student's t test.
C. parvum injections.-C. parvum was
given either i.v. as a dose of 0 44 mg diluted
to 0-2 ml in normal saline, or i.p. or s.c. as
0'7 mg in 0 1 ml to untreated mice or to mice
immediately after implantation of tumour.
Distribution studies.-Groups of 5 mice
were anaesthetized with ether and exsan-
guinated from the retro-orbital sinus at 4 h
and 1, 3, 7 and 14 days after injection of
labelled C. parvum. Peritoneal cells were
collected after injecting 3 ml of heparinized
saline, i.p., and aspirating the cell-containing
fluid after abdominal massage. The follow-
ing tissues were removed for study: liver,
spleen, mesenteric lymph nodes, small gut,
kidney, thymus, lungs, heart, brain, skin,
muscleandfemoralbonemarrow. Intumour-
bearing mice, the tumour and draining lymph
nodes were also removed. Tissues were
dissected free of connective tissue, rinsed in
saline, blotted dry and weighed. In a
separate experiment, bladder urine, faeces
and gut contents were collected from groups
of 3 mice. Whole organs, or samples of
tissues up to 200 mg in weight, were added to
scintillation vials containing 1 ml of the
tissue solvent, Soluene-350 (Packard); when
there was sufficient tissue, samples were
studied in triplicate. 10 ml of scintillant
(500 ml Triton x 100, 1 1 toluene and 6 g
PPO) was added to the dissolved tissues, and
the samples counted on an " Intertechnique "
liquid scintillation spectrometer. An inter-
nal standard was used to correct for quench.
Calculations.-The radioactivity of each
whole organ was determined and expressed as
a percentage of the total injected dose. The
total radioactivity in the blood was taken
to be that in a 1-5 ml volume. Mean values
and standard deviations were calculated for
all experimental groups.
Autoradiography.-Liver, spleen, small
gut and brain were excised 3 days after i.v. or
i.p. injection oflabelled C. parvum. Tumour
was studied 7 and 14 davs after i.v. injection
of the vaccine. The tissues were fixed in
formol saline and autoradiographs were
prepared using the standard stripping-film
technique (Pelc, 1956). Histological sections
were stained with haematoxylin and eosin.
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RESULTS
Somebiologicalproperties oflabelledCoryne-
bacterium parvum
Antitumour action.-Fig. 1 shows the
effect of labelled and control C. parvum
on the growth of the primary Lewis
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no significant difference in tumour growth
between the 2 forms of C. parvum after
similar routes of injection.
The numbers ofpulmonary metastases
found 21 days after tumour implantation
are shown in the Table. There was
significant reduction (P < 0O001) ofmetas-
tases in all mice which received C. parvum.
But there was no difference in the number
of metastases between the different C.
parvum groups.
Hepatosplenomegaly.-Groups of5 mice
were injected i.v. with labelled C. parvum
and killed 4 h and 1, 3, 7 and 14 days
after injection. The whole body, liver,
spleen and thymus were weighed at each
interval after injection (Fig. 2.). There
was an increase in the weight of the liver
and spleen, and a decrease in that of the
thymus. There was a slight drop in body
weight, which had returned to normal by
14 days after C. parvum.
Distribution of C. parvum in normal mice
TA - - A A- -, L_ &_, intravenous n3ecaton.-Ilne clstrliu-
tion ofactivity after i.v. injection of [3H)
DAYS thymidine-labelled C. parvum is shown in
1.-The effectof [3H] thymidine-labelled Fig. 3. Activity was rapidly cleared from
parvumgiveneitheri.v. *--- *,ori.p. the blood: only 02% of the injected dose
1 - , and control C. parvum i.v. O could be recovered 4h after injection.
-- O, or i.p. C] CD on the growth of This value rose to 0.75% on Days 1 and 3,
heprimaryLewislungcarcinoma. Control and subsequently fell. Only moderate iice were given saline x x. Each
oint represents the mean of 6-8 mice and counts were detected in the lungs: 4% of
ar denotes s.e. the injected dose was present at 4 h and
this value thereafter decreased. Highest
)ur when injected either i.v. or i.p. at activity was found in the liver: 4 h after
game time as tumour into groups of 8 injection the liver contained 59% of the
C. parvum caused a significant injected dose, by 1 and 3 days it was 36%
)ition of tumour growth when com- and at 7 days it had fallen to 20%. By
I with that in control mice given 14 days only 10% was detected.
e (on Day 21. P = 0 001). There was Moderate amounts of radioactive label
TABLE-The Effect of [3H] Thymidine-labelled and Control
C. parvum on Metastasesfrom the Lewis Lung Tumour
Mean metastases
No. ofmice ± s.d.
a. Saline 7 36+9
b. Control C. parvum i.v. 8 8±6
c. [3H] thymidine C. parvum i.v. 6 5+3
d. Control C. parvum i.p. 8 7±5
e. [3H] thymidine C. parvum i.p. 6 7+5
Significance by Student's t test: a: b, c, d, or e <0001; b: c, d, e not significant.
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FIG. 2. Liver, spleen, thymus and whole body weights at intervals after i.v. injection of [3H]
thymidine-labelled C. parvum. Each figure is the mean from 5 mice and bar denotes s.d.
were recorded in the spleen (2-5% at 4 h,
3% at 1 day and 1-15% at later times)
and the small gut (1 50o at 4 h, 6 o at 1
day and progressively less thereafter). In
the peritoneal fluid and brain, only slight
activity was detected, and no consistently
significant levels of radioactivity were
recovered from the mesenteric lymph
nodes, thymus, heart, bone marrow, skin
or muscle.
Intraperitoneal injection. The distri-
bution of radioactivity after i.p. injection
of labelled C. parvum is shown in Fig. 4.
Activity was rapidly cleared from the
peritoneal cavity. At 4 h after injection
only 8% ofthe injected dose was recorded.
This value had decreased to 400 at 1 day,
and there was a further reduction to 300
at 3 days and to 10/ at 7 days. Highest
activity was found in the liver. At 4 h,
26% was detected. This value gradually
decreased, until only 400 was present at
14 days. Moderate amounts of radio-
active label were recovered from the
spleen (400 at 4 h, thereafter decreasing)
and the small gut (2.5% at 4 h, gradually
increasing to a maximum of5% at 3 days).
A moderate count (3 50o) was recorded in
the lungs at 4 h, but little was found at
later times. Only slight activity was
found in the brain and blood, and no
consistently significant activity was re-
covered from the mesenteric lymph nodes,
thymus, heart, bone marrow, skin or
muscle.
Subcutaneous injection. The distribu-
tion of activity after sec. injection of
radiolabelled C. parvurn is shown in Fig. 5.
After this route of injection, highest
activity was recovered from the site of
injection. Seventy-one per cent of the
injected dose was detected at 4 h after
injection, and a similar number of counts
were found at Day 1. However, by 3
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FiG. 3. Distribution of activity recovered as % of total injected dose, in various tissues at 4 h, and
1, 3, 7 and 14 days after i.v. injection of [3H] thymidine-labelled C. parvum in normal mice. Each
histogram block represents the mean value from 5 animals and bar denotes s.d.
days the value had diminished to 3700,
and by Day 14 only 20% was recovered.
Very little radioactive label was detected
in the lymph nodes draining the site of
injection, just 0 1% on Days 3 and 7.
Moderate counts were recovered from the
liver and small gut, both increasing to a
maximum on Day 3, of 20% and 4 0
respectively. In the spleen, peritoneal
fluid, brain and blood, only slight radio-
activity was detected, and no consistently
significant level of activity was found in
thelungs, mesentericlymphnodes,thymus,
heart, bone marrow, skin or muscle.
Lossofradioactivity.-After allroutes of
injection, there was a loss of activity (Fig.
3, 4 and 5). At 14 days after injection,
only 5-10%0 of the injected dose was
recovered. There was no difference in the
activities detected in the kidney, urine,
faeces and gut contents after i.v., i.p. or
s.c. injection. However, the values did
vary from mouse to mouse. Between
0-2% and 1.0% of the injected dose was
found in the kidney at all times after
injection. Up to 5%0 was found in 0 1 ml
urine and 2-3% in the content ofboth the
small and large bowel at 4 h, and 1 and 3
days after injection. Less activity was
recorded at 7 and 14 days.
Distribution of C. parvum in tumour-
bearing mtce
Radiolabelled C. parvum was injected
i.v., i.p., or s.c. on the same day as the
mice were inoculated s.c. with Lewis lung
carcinoma. The distribution of radio-
activity in these tumour-bearing mice was
found to be similar to that in normal mice
(Figs. 3, 4 and 5). The radioactive label
detected in tumour after the different
routes of injection is shown in Fig. 6a.
There was an increase in activity, which
correlated to some extent with tumour
size. Up to 3 days after injection, tumour
weights varied between 90 and 110 mg,
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FIG. 4.-Distribution of activity recovered as % of total injected dose, in various tissues at 4 h and,
1, 3, 7 and 14 days after i.p. injection of [3H] thymidine-labelled C. parvum in normal mice. Each
histogram block represents the mean value from 5 animnals and bar denotes s.d.
and the counts recorded between 0.1 and
0 2% of the injected dose. By 7 days
after i.v. injection, tumour weight had
increased to 275 mg, and the activity
recovered to 1.3%. However, by 14days,
when tumour weight was 1202 mg, only
1.4% was detected. After i.p. injection,
0-9% of the injected dose was found in
tumours weighing 181 and 1365 mg, at 7
and 14 days after injection, respectively.
Seven days after s.c. injection, 1-0% was
found in tumours weighing 520 mg. This
value rose to 2.3% by 14 days, when
tumour weighed 2145 mg. No signifi-
cant activity was recovered from the
lymph nodes draining these tumours.
A higher level of activity was found in
tumour when C. parvum was injected i.v.
7 days after tumour inoculation (Fig. 6b).
2.9% of the injected dose was detected at
1 day, when tumour weighed 453 mg. By
14 days the activity recovered had risen
to 5.6% and tumour weight to 1714 mg.
0.1% of the injected dose was recorded in
the lymph nodes draining these tumours.
Autoradiography
Autoradiographs were prepared from
liver, spleen, small gut and brain taken
from mice 3 days after i.v. or i.p. injection
of labelled C. parvum. Tumour was
studied either 14 days after i.v. injection
of C. parvum from mice given the vaccine
at the same time as tumour inoculation, or
7 days after injection when the vaccine
was given 7 days after tumour.
Liver.-The liver was heavily labelled
(Fig. 7). Grains were observed in the
cytoplasm of Kuppfer cells and in histio-
cytes around the periphery ofgranulomas.
(Systemic C. parvum is known to cause
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FIG. 5.-Distribution of activity recovered as % of total injected dose, in various tissues at 4 h, and
1, 3, 7 and 14 days after s.c. injection of[3H] thymidine-labelled C. parvum. Eachhistogram block
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FIG. 7.-Photomicroautoradiograph (x 1750) of liver, under oil immersion. In the centre of the
picture are labelled Kupffer cells. Part of a granulomatous lesion is present lower right.
granuloma formation in the liver (Castro,
1974b; Mosedale and Smith, 1975).)
Spleen.-Grains were observed in the
phagocytic cells of the spleen (Fig. 8).
These were mainly present in the red pulp,
in the sinus lining cells and the chords.
A few labelled cells were found in the
white pulp near the marginal sinus.
Small gut.-Only 2 labelled cells were
found in the small gut sections and both of
these were phagocytic. One was ob-
served in the lamina propria and the other
in the gut lumen. No label was found in
gut epithelium or crypts of Lieberkiihn.
Brain.-There were no labelled cells
in the sections of brain which were
examined.
Tumour.-Many dividing tumour cells
were seen. No labelled cells were ob-
servedinthesectionswhichwereexamined.
DISCUSSION
An ideal radioactive marker for the
determination ofthe location ofC. parvum
after injection would be labelled cell wall
or inner wall membrane, since it is these
constituents which stimulate the reticulo-
endothelial system (Adlam, Reid &
Torkington, 1975). However, the avail-
able nutrients for the incorporation of
radiolabel into these sites are the 14C_ or
3H-labelled sugars and glycerol, and these
substances are extensively degraded to
CO2 during growth of the bacteria under
anaerobic conditions. Another method of
labelling the cell wall would be to iodinate
a killed bacterial suspension, using Chlora-
mine T and 1251 (Hunter, 1973). How-
ever, we considered that this technique,
which substitutes 1251 into the surface
tyrosine groups, might alter the bacterial
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FIG. 8.-Photomicroautoradiograph ('x 1750) of spleen under oil immersion. Many labelled
phagocytic cells are present in the red pulp.
cell wall and consequently change the
in vivo distribution of C. parvunm.
We therefore chose to label the DNA
within the bacterium as an alternative,
since little or no degradation of DNA
precursors should occur during anaerobic
growth, and no substantial change in
cellular structure should result. We ob-
tained highly labelled bacteria with little
or no low-mol.-wt. materials in the
bacterial suspensions which were used for
injection.
The labelled formalin-killed C. parvurn
was found to be morphologically similar
to an unlabelled vaccine obtained from
Burroughs Wellcome, which had been
prepared using a similar technique. This
labelled C. parvrum was shown to have
similar biological properties to the com-
mercial vaccine. Lewis lung carcinoma
was used to test the antitumour properties
of labelled C. parvum, as we have studied
this tumour system in detail (Sadler and
Castro, 1975, 1976a). There were no
differences in the antitumour or anti-
metastatic effects of the labelled C.
parvum and unlabelled commercial C.
parvum. J.v. injection of labelled C.
parvum caused an increase in liver and
spleen weight and a decrease in that of
the thymus. Similar weight changes after
injection of commercial C. parvum have
been reported elsewhere (Halpern et al.,
1963; Castro, 1974b) and these particular
weights were not significantly different
from those found previously in this
laboratory, using unlabelled C. parvum
in the same strain of mouse (Sadler and
Castro, 1976a).
The labelled C. parvum was injected
i.v., i.p., or s.c. into normal mice and its
localization up to 14 days after injection
365T. E. SADLER, W. A. CRAMP AND J. E. CASTRO
determined. The distribution of activity
after i.v. or i.p. injection was similar, in
that highest counts were found in the liver
and moderate activity was recovered from
the spleen, lungs and small gut. After
both routes of injection, activity was
rapidly cleared from the site of injection.
The localization of activity after s.c.
injection was quite different, for the
majority ofcounts were found at the site of
injection and little was recovered in other
tissues. This difference in localization is
probably the reason why i.v.- or i.p.-
injected C. parvum causes hepatospleno-
megaly and inhibits tumour growth to a
greater extent than s.c.-injected vaccine
(Sadler and Castro, 1976a).
This varied distribution of C. parvum
after different routes ofinjection might be
important in the clinical treatment of
localizedtumour or metastases. Inrecent
studies (Likhite and Halpern, 1974; Scott,
1974b; Woodruff and Dunbar, 1975) C.
parvum-enhanced specific anti-tumour
immunity has been shown after injection
of the vaccine directly into tumour,
suggesting that contact of C. parvum and
tumour may be an advantage in treat-
ment. Subcutaneous (or intra-tumour)
injection of C. parvum might be used
against skin tumours, i.v. injection against
liver or lung tumours and i.p. injection
against ascitic tumours. In our own
studies, using the Lewis lung carcinoma,
we found i.v. or i.p. C. parvum equally
effective in inhibiting pulmonary metas-
tases (Sadler and Castro, 1975).
The role of immunotherapy in the
treatment of brain tumours is not clear.
Our observation that only low levels of
activity were present in brains after
injection of labelled C. parvum correlates
well with the finding that C. parvum has
only slight inhibitory effects on the growth
and induction of experimental intra-
cerebral tumours (Osborn, Sadler and
Castro, 1977). This result was not unex-
pected, as the blood-brain barrier allows
only a poor immunological response to
antigen within the brain (Holman, 1972;
Medawar, 1948; Denlinger et at., 1975).
After all routes of injection, there was
a loss of activity, so that by 14 days after
injection of labelled C. parvum, only 5-
10% of the injected dose could be re-
covered from the tissues sampled. This
radioactive label was excreted in both the
urine and faeces. No investigations were
made to determine whether this activity
was in the form oflabelled C. parvum or as
free [3H] thymidine.
The distribution of labelled C. parvum
in mice bearing Lewis tumourwas found to
be similar to that in normal mice. Acti-
vity was recovered fromtumour, butthere
was no direct relationship between the
effectiveness of the vaccine in inhibiting
tumour growth and the counts recorded
inthetumour. IndeedwhenC.parvum was
administered at the same time as tumour
inoculation, the higher levels of activity
were detected in the larger tumours which
grew in the s.c.-treated mice. However,
highest radioactive counts were recovered
from tumour when C. parvum was given
i.v. 7 days after tumour. C. parvum
administered at this time, when the
tumour is fully vascularized and about
1 cm in diameter, has been shown to be
effective in inhibiting tumour growth
(Sadler and Castro, 1976a).
Autoradiographs were prepared from
small gut, brain, tumour, liver and spleen.
Radioactive label was found only in the
cytoplasm of phagocytic cells. Cells with
label over the nucleus were sought, but
not found, in the epithelium and crypts of
Lieberkuhn of the small gut, and in
tumour, where cell division occurs rapidly,
The absence of radioactivity in nuclear
DNA is indicative that very little or no
[3H] thymidine was lost from the bacteria
after injection. Indeed, it seems unlikely
that the thymidine would be lost, as
evidence from other bacterial systems
suggest that, even after enzymatic and
detergent disruption, detachment of DNA
from cell wall or inner wall membranes can
only be achieved by considerable mechani-
cal disruption (Fielding and Fox, 1970).
In the small gut, only 2 labelled cells
were detected and both of these were
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macrophages. One was observed in the
lamina propria and the other in the gut
lumen. Up to 3 days after injection of
labelled C. parvum, there was a gradual
increase in activity recovered in the small
gut, whereas in other tissues, except
tumour, there was a loss of activity.
There is some evidence for the migration
of Kupffer cells to the, lungs (Vernon-
Roberts, 1972), and it is possible (though
not proven by the observation of only
2 cells) that macrophages migrate from
the liver or some other tissue to the lamina
propria of the small gut and into the gut
lumen. Indeed, moderate counts were
recorded in the gut contents.
In the brain, no labelled cells were
observed in the sections studied. The
activity recovered after injection of lab-
elled C. parvum was relatively low, and
therefore very few labelled cells must have
been present. Similarly, no labelled cells
were found in tumour.
Labelled phagocytic cells were most
numerous in the liver and spleen. After
all routes of injection, C. parvum was
rapidly cleared from the blood, and it is
probable that these macrophages were
responsible for the clearance.
The antitumour action of 0. parvum is
thought to be mediated by activated
macrophages (Scott, 1974c; Ghaffar, Cul-
len and Woodruff, 1975). The uptake of
this vaccine by these cells may be import-
ant in the initiation of the response. At
present, it is unclear whether T cells are
also required for the anti-tumour action
of C. parvum (Woodruff, Dunbar and
Ghaffar 1973; Christie and Bomford,
1975; Sadler and Castro, 1976b).
We therefore conclude that in vitro
labelling of living C. parvum with [3H]
thymidine, followed by formalin killing, is
a satisfactory technique for producing a
radiolabelled killed C. parvum which
retains the same btological properties as
unlabelled killed C. parvum. Our deter-
mination of the tissue localization of C.
parvum after various routes of injection
could be of use in the elucidation of the
mechanism ofaction ofthis vaccine and in
the drafting ofprotocols for clinical trials.
The authors would like to thank
Burroughs Wellcome for the gift of live
C. parvum, Margaret Blount for preparing
the autoradiographs, and Dr I. Lampert
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